These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 31790636)

  • 21. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
    Chen CW; Armstrong SA
    Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
    Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
    J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of the Lysosome-Associated Membrane Protein LAMP5 by DOT1L Serves as a Bodyguard for MLL Fusion Oncoproteins to Evade Degradation in Leukemia.
    Wang WT; Han C; Sun YM; Chen ZH; Fang K; Huang W; Sun LY; Zeng ZC; Luo XQ; Chen YQ
    Clin Cancer Res; 2019 May; 25(9):2795-2808. PubMed ID: 30651276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DOT1L and H3K79 Methylation in Transcription and Genomic Stability.
    Wood K; Tellier M; Murphy S
    Biomolecules; 2018 Feb; 8(1):. PubMed ID: 29495487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
    Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
    Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
    Daigle SR; Olhava EJ; Therkelsen CA; Basavapathruni A; Jin L; Boriack-Sjodin PA; Allain CJ; Klaus CR; Raimondi A; Scott MP; Waters NJ; Chesworth R; Moyer MP; Copeland RA; Richon VM; Pollock RM
    Blood; 2013 Aug; 122(6):1017-25. PubMed ID: 23801631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of
    Lonetti A; Indio V; Laginestra MA; Tarantino G; Chiarini F; Astolfi A; Bertuccio SN; Martelli AM; Locatelli F; Pession A; Masetti R
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32698374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells.
    Steger DJ; Lefterova MI; Ying L; Stonestrom AJ; Schupp M; Zhuo D; Vakoc AL; Kim JE; Chen J; Lazar MA; Blobel GA; Vakoc CR
    Mol Cell Biol; 2008 Apr; 28(8):2825-39. PubMed ID: 18285465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The upstreams and downstreams of H3K79 methylation by DOT1L.
    Vlaming H; van Leeuwen F
    Chromosoma; 2016 Sep; 125(4):593-605. PubMed ID: 26728620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The DNA damage-independent ATM signalling maintains CBP/DOT1L axis in MLL rearranged acute myeloid leukaemia.
    Wang G; Zhang W; Ren J; Zeng Y; Dang X; Tian X; Yu W; Li Z; Ma Y; Yang P; Lu J; Zheng J; Lu B; Xu J; Liang A
    Oncogene; 2024 Jun; 43(25):1900-1916. PubMed ID: 38671157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Dysregulated DNA Methylation Landscape Linked to Gene Expression in MLL-Rearranged AML.
    Koldobskiy MA; Abante J; Jenkinson G; Pujadas E; Tetens A; Zhao F; Tryggvadottir R; Idrizi A; Reinisch A; Majeti R; Goutsias J; Feinberg AP
    Epigenetics; 2020 Aug; 15(8):841-858. PubMed ID: 32114880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias.
    Yi Y; Ge S
    J Hematol Oncol; 2022 Mar; 15(1):35. PubMed ID: 35331314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
    Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
    J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucocorticoid sensitisation in Mixed Lineage Leukaemia-rearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101.
    Spijkers-Hagelstein JA; Schneider P; Pinhanços SM; Garrido Castro P; Pieters R; Stam RW
    Eur J Cancer; 2014 Jun; 50(9):1665-74. PubMed ID: 24703900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MLL leukemia induction by genome editing of human CD34+ hematopoietic cells.
    Buechele C; Breese EH; Schneidawind D; Lin CH; Jeong J; Duque-Afonso J; Wong SH; Smith KS; Negrin RS; Porteus M; Cleary ML
    Blood; 2015 Oct; 126(14):1683-94. PubMed ID: 26311362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
    Anglin JL; Song Y
    J Med Chem; 2013 Nov; 56(22):8972-83. PubMed ID: 23879463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L.
    Anglin JL; Deng L; Yao Y; Cai G; Liu Z; Jiang H; Cheng G; Chen P; Dong S; Song Y
    J Med Chem; 2012 Sep; 55(18):8066-74. PubMed ID: 22924785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MLL leukemia and future treatment strategies.
    Marschalek R
    Arch Pharm (Weinheim); 2015 Apr; 348(4):221-8. PubMed ID: 25740345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.
    Kari V; Raul SK; Henck JM; Kitz J; Kramer F; Kosinsky RL; Übelmesser N; Mansour WY; Eggert J; Spitzner M; Najafova Z; Bastians H; Grade M; Gaedcke J; Wegwitz F; Johnsen SA
    Clin Epigenetics; 2019 Jan; 11(1):4. PubMed ID: 30616689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.